|
[1]
|
卞如濂. 吸入型糖皮质激素的药理学特性[J]. 中国实用儿科杂志, 2000(7): 440-441.
|
|
[2]
|
Kearns, N., Maijers, I., Harper, J., et al. (2020) Inhaled Corticosteroids in Acute Asthma: A Systemic Review and Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice, 8, 605-617.E6. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Ora, J., Calzetta, L., Matera, M.G., et al. (2020) Advances with Glucocorticoids in the Treatment of Asthma: State of the Art. Expert Opinion on Pharmacotherapy, 21, 2305-2316. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Global Initiative for Asthma (2021) Global Strategy for Asthma Management and Prevention.
https://www.ginasthma.org/
|
|
[5]
|
陈萍, 赵海涛. β2受体激动剂在支气管哮喘治疗中的合理应用[J]. 中华哮喘杂志(电子版), 2008, 2(3): 220-223.
|
|
[6]
|
Nelson, H.S., Weiss S.T., Bleecker E.R., et al. (2006) The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest, 129, 15-26. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Kobayashi, Y., Mercado, N., Miller-Larsson, A., et al. (2012) In-creased Corticosteroid Sensitivity by a Long Acting β2 Agonist Formoterol via β2 Adrenoceptor Independent Protein Phosphatase 2A Activation. Pulmonary Pharmacology & Therapeutics, 25, 201-207. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Nwaru, B.I., Ekström, M., Hasvold, P., et al. (2020) Overuse of Short-Acting β2-Agonists in Asthma Is Associated with Increased Risk of Exacerbation and Mortality: A Nationwide Cohort Study of the Global SABINA Programme. European Respiratory Journal, 55, Article ID: 1901872. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
黄娟, 陈颖, 龙珍, 等. 抗胆碱能药物——噻托溴铵治疗儿童哮喘疗效观察[J]. 中国妇幼保健, 2015, 30(13): 2005-2008.
|
|
[10]
|
Cazzola, M., Calzetta, L. and Matera, M.G. (2021) Long-Acting Muscarinic Antagonists and Small Airways in Asthma: Which Link? Allergy, 76, 1990-2001. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Cazzola, M., Ora, J., Rogliani, P., et al. (2017) Role of Muscarinic An-tagonists in Asthma Therapy. Expert Review of Respiratory Medicine, 11, 239-253. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Kew, K.M. and Dahri, K. (2016) Long-Acting Muscarinic Antagonists (LAMA) Added to Combination Long-Acting Beta2-Agonists and Inhaled Corticosteroids (LABA/ICS) versus LABA/ICS for Adults with Asthma. Cochrane Database of Systematic Reviews, 6, CD011721. [Google Scholar] [CrossRef]
|
|
[13]
|
江波. 格隆溴铵临床前药效学和药代动力学研究[D]: [博士学位论文]. 杭州: 浙江大学, 2018.
|
|
[14]
|
Papi, A., Virchow, J.C., Singh, D., et al. (2021) Extrafine Triple Therapy and Asthma Exacerbation Seasonality: TRIMARAN and TRIGGER post hoc Analyses. Journal of Allergy and Clinical Immunology, 148, 262-265.E2. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
郭海英, 周新. 新抗胆碱能药物格隆溴铵[J]. 上海医药, 2013(15): 10-12.
|
|
[16]
|
Kirkland, S.W., Vandenberghe, C., Voaklander, B., et al. (2017) Combined Inhaled Beta-Agonist and Anticholinergic Agents for Emergency Management in Adults with Asthma. Cochrane Database of Systematic Reviews, 1, CD001284. [Google Scholar] [CrossRef]
|
|
[17]
|
朱珍丽. 抗胆碱能药物在儿童哮喘治疗中的研究进展[J]. 国际儿科学杂志, 2020, 47(8): 561-564.
|
|
[18]
|
Barnes, P.J. (2013) Theophylline. American Journal of Respiratory and Critical Care Medicine, 188, 901-906. [Google Scholar] [CrossRef]
|
|
[19]
|
叶伶, 金美玲. 茶碱类药物的研究进展及其临床应用[J]. 世界临床药物, 2009, 30(1): 23-26.
|
|
[20]
|
贺金莲. 茶碱类药治疗哮喘作用评价[J]. 中国医院用药评价与分析, 2008, 8(3): 176-177.
|
|
[21]
|
中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2020年版) [J]. 中华结核和呼吸杂志, 2020, 43(12): 1023-1048.
|
|
[22]
|
刘锋, 钟丽球. 孟鲁司特钠药理作用及临床应用研究[J]. 临床合理用药杂志, 2017, 10(12): 83-84.
|
|
[23]
|
McGregor, M.C., Krings, J.G., Nair, P., et al. (2019) Role of Biologics in Asthma. American Journal of Respiratory and Critical Care Medicine, 199, 433-445. [Google Scholar] [CrossRef]
|
|
[24]
|
Manka, L.A. and Wechsler, M.E. (2018) Selecting the Right Biologic for Your Patients with Severe Asthma. Annals of Allergy, Asthma & Immunology, 121, 406-413. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
McCracken, J.L., Tripple, J.W. and Calhoun, W.J. (2016) Biologic Therapy in the Management of Asthma. Current Opinion in Allergy & Clinical Immunology, 16, 375-382. [Google Scholar] [CrossRef]
|
|
[26]
|
Hanania, N.A., et al. (2011) Omalizumab in Severe Allergic Asthma Inadequately Controlled with Standard Therapy: A Randomized Trial. Annals of Internal Medicine, 154, 573-582. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Niven, R.M., Saralaya, D., Chaudhuri, R., et al. (2016) Impact of Omalizumab on Treatment of Severe Allergic Asthma in UK Clinical Practice: A UK Multicentre Observational Study (the APEX II Study). BMJ Open, 6, e11857. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Pelaia, C., Calabrese, C., Barbuto, S., et al. (2019) Omalizumab Lowers Asthma Exacerbations, Oral Corticosteroid Intake and Blood Eosinophils: Results of a 5-YEAR Single-Centre Observational Study. Pulmonary Pharmacology & Therapeutics, 54, 25-30. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Agache, I., Beltran, J., Akdis, C., et al. (2020) Efficacy and Safety of Treatment with Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma. A Systematic Review for the EAACI Guidelines—Recommendations on the Use of Biologicals in Severe Asthma. Allergy, 75, 1023-1042. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
李靖. 奥马珠单抗治疗过敏性哮喘的中国专家共识[J]. 中华结核和呼吸杂志, 2018, 41(3): 179-185.
|
|
[31]
|
Di Bona, D., Fiorino, I., Taurino, M., et al. (2017) Long-Term Real-Life Safety of Omalizumab in Patients with Severe Uncontrolled Asthma: A Nine-Year Study. Respiratory Medicine, 130, 55-60. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Hillas, G., Fouka, E. and Papaioannou, A.I. (2020) Antibodies Targeting the Interleukin-5 Signaling Pathway Used as Add-On Therapy for Patients with Severe Eosinophilic Asthma: A Review of the Mechanism of Action, Efficacy, and Safety of the Subcutaneously Administered Agents, Mepolizumab and Benralizumab. Expert Review of Respiratory Medicine, 14, 353-365. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Khurana, S., Brusselle, G.G., Bel, E.H., et al. (2019) Long-Term Safety and Clinical Benefit of Mepolizumab in Patients with the Most Severe Eosinophilic Asthma: The COSMEX Study. Clinical Therapeutics, 41, 2041-2056. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Ortega, H.G., Liu, M.C., Pavord, I.D., et al. (2014) Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. The New England Journal of Medicine, 371, 1198-1207. [Google Scholar] [CrossRef]
|
|
[35]
|
Harvey, E.S., Langton, D., Katelaris, C., et al. (2020) Mepolizumab Effectiveness and Identification of Super-Responders in Severe Asthma. The European Respiratory Journal, 55, Article ID: 1902420. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Pavord, I.D., Korn, S., Howarth, P., et al. (2012) Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial. The Lancet, 380, 651-659. [Google Scholar] [CrossRef]
|
|
[37]
|
Chupp, G.L., Bradford, E.S., Albers, F.C., et al. (2017) Efficacy of Mepolizumab Add-On Therapy on Health-Related Quality of Life and Markers of Asthma Control in Severe Eosinophilic Asthma (MUSCA): A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase 3b Trial. The Lancet Respiratory Medicine, 5, 390-400. [Google Scholar] [CrossRef]
|
|
[38]
|
Khatri, S., Moore, W., Gibson, P.G., et al. (2019) Assess-ment of the Long-Term Safety of Mepolizumab and Durability of Clinical Response in Patients with Severe Eosinophilic Asthma. Journal of Allergy and Clinical Immunology, 143, 1742-1751. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Wechsler, M.E., Hickey, L., Garin, M. et al. (2020) Efficacy of Reslizumab Treatment in Exacerbation-Prone Patients with Severe Eosinophilic Asthma. The Journal of Allergy and Clinical Immunology: In Practice, 8, 3434-3442. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Murphy, K., Jacobs, J., Bjermer, L., et al. (2017) Long-Term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. The Journal of Allergy and Clinical Immu-nology: In Practice, 5, 1572-1581.E3. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Castro, M., Zangrilli, J., Wechsler, M.E., et al. (2015) Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Counts: Results from Two Multicentre, Parallel, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trials. The Lancet Respiratory Medicine, 3, 355-366. [Google Scholar] [CrossRef]
|
|
[42]
|
Bjermer, L., Lemiere, C., Maspero, J., et al. (2016) Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest, 150, 789-798. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Virchow, J.C., Katial, R., Brusselle, G.G., et al. (2020) Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials. The Journal of Allergy and Clinical Immunology: In Practice, 8, 540-548. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Pelaia, C., Calabrese, C., Vatrella, A., et al. (2018) Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. BioMed Research International, 2018, Article ID: 4839230. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Harrison, T.W., Chanez, P., Menzella, F., et al. (2021) Onset of Effect and Impact on Health-Related Quality of Life, Exacerbation Rate, Lung Function, and Nasal Polyposis Symptoms for Patients with Severe Eosinophilic Asthma Treated with Benralizumab (ANDHI): A Randomised, Controlled, Phase 3b Trial. The Lancet Respiratory Medicine, 9, 260-274.
|
|
[46]
|
Bleecker, E.R., FitzGerald, J.M., Chanez, P., et al. (2016) Efficacy and Safety of Benralizumab for Pa-tients with Severe Asthma Uncontrolled with High-Dosage Inhaled Corticosteroids and Long-Acting β2-Agonists (SIROCCO): A Randomised, Multicentre, Placebo-Controlled Phase 3 Trial. The Lancet, 388, 2115-2127. [Google Scholar] [CrossRef]
|
|
[47]
|
Nair, P., Wenzel, S., Rabe, K.F., et al. (2017) Oral Gluco-corticoid—Sparing Effect of Benralizumab in Severe Asthma. The New England Journal of Medicine, 376, 2448-2458. [Google Scholar] [CrossRef]
|
|
[48]
|
Busse, W.W., Bleecker, E.R., FitzGerald, J.M., et al. (2019) Long-Term Safety and Efficacy of Benralizumab in Patients with Severe, Uncontrolled Asthma: 1-Year Results from the BORA Phase 3 Extension Trial. The Lancet Respiratory Medicine, 7, 46-59.
|
|
[49]
|
王艳泓, 邱玉英. 支气管哮喘的生物靶向治疗机制、现状及展望[J]. 中华肺部疾病杂志(电子版), 2019, 12(6): 790-793.
|
|
[50]
|
Castro, M., Corren, J., Pavord, I.D., et al. (2018) Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. The New England Journal of Medicine, 378, 2486-2496. [Google Scholar] [CrossRef]
|
|
[51]
|
Rabe, K.F., Nair, P., Brusselle, G., et al. (2018) Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. The New England Journal of Medicine, 378, 2475-2485. [Google Scholar] [CrossRef]
|
|
[52]
|
Corren, J., Castro, M., O’Riordan, T., et al. (2020) Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. The Journal of Allergy and Clinical Immunology: In Practice, 8, 516-526.
|
|
[53]
|
Hoy, S.M. (2022) Tezepelumab: First Approval. Drugs, 82, 461-468. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Corren, J., Parnes, J.R., Wang, L., et al. (2017) Tezepelumab in Adults with Uncontrolled Asthma. The New England Journal of Medicine, 377, 936-946. [Google Scholar] [CrossRef]
|
|
[55]
|
Menzies-Gow, A., Corren, J., Bourdin, A., et al. (2021) Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. The New England Journal of Medicine, 384, 1800-1809. [Google Scholar] [CrossRef]
|
|
[56]
|
Corren, J., Ambrose, C.S., Salapa, K., et al. (2021) Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy. The Journal of Allergy and Clinical Immunology: In Practice, 9, 4334-4342.E6. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Diver, S., Khalfaoui, L., Emson, C., et al. (2021) Effect of Tezepelumab on Airway Inflammatory Cells, Remodelling, and Hyperresponsiveness in Patients with Moder-ate-to-Severe Uncontrolled Asthma (CASCADE): A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial. The Lancet Respiratory Medicine, 9, 1299-1312. [Google Scholar] [CrossRef]
|
|
[58]
|
Gibson, P.G., Yang, I.A., Upham, J.W., et al. (2017) Effect of Azithromycin on Asthma Exacerbations and Quality of Life in Adults with Persistent Uncontrolled Asthma (AMAZES): A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 390, 659-668. [Google Scholar] [CrossRef]
|